NightHawk's plan to merge with Virtual Radiologic should help unlock shareholder value.
Fresenius remains well-positioned to prosper despite potential regulatory hurdles.
Virtual Radiologic's strength in the finals market should provide ample growth opportunities.
Cost control allows Psychiatric Solutions to deliver strong results despite reimbursement uncertainty.
DaVita holds steady in spite of a changing regulatory environment for dialysis.
We think poor execution may interfere with NightHawk's ability to fully benefit from favorable industry trends.
Psychiatric Solutions is well-positioned in the behavioral health industry.
Sale of MDS's analytical business should close by the end of the first quarter.
Fresenius relies on Medicare and Medicaid reimbursements for about 35% of its revenue, leaving the company vulnerable to unforeseen changes in reimbursement rates.DaVita's acquisition of Gambro Healthcare included an agreement to purchase dialysis products from Gambro. As DaVita was a previously
We are raising our fair value estimate for Virtual Radiologic VRAD after increasing our near-term growth assumptions for the firm. Although we have remained optimistic about Virtual Radiologic's long-run prospects, we slightly lowered our fair value estimate last year following the company's